Links to Data sources

Sr. No Display Name Type Country Last Updated
1 Health Search/CSD LPD Data Source Italy 25/06/2014

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe Ms Novartis Clinical Disclosure Officer 22/02/2021
Finalised Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Ms Clinical Disclosure Officer Novartis 23/11/2020
Finalised Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe Ms Clinical Disclosure Officer Novartis 18/11/2020
Finalised Multinational database cohort study to assess RMP-specified safety outcomes in association with indacaterol/glycopyrronium bromide in Europe Ms Clinical Disclosure Officer Novartis 23/09/2020
Finalised European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance Dr Daniel Prieto-Alhambra 22/03/2018
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies Professor Miriam Sturkenboom 25/08/2017
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies Professor Miriam Sturkenboom 25/08/2017
Finalised Arrhythmogenic Potential of Drugs Professor Miriam Sturkenboom 25/08/2017
Ongoing Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine Dr Heather Rubino 06/10/2021
Ongoing Drug Utilization Study (DUS) and post authorization safety study (PASS) on the fixed combination Tramadol-Dexketoprofen (DKP-TRAM) Dr Lapi Francesco 26/05/2021
Ongoing Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure Ms Novartis Clinical Disclosure Officer 05/05/2021
Ongoing Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®) Ms Novartis Clinical Disclosure Office 05/05/2021
Ongoing ACCESS template protocol for safety of COVID-19 vaccines Professor Miriam Sturkenboom 19/02/2021
Ongoing VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006) Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform Dr Roberto Giuseppe 14/02/2019
Planned An Observational Post-Authorisation Safety Study of Lesinurad Patients Dr Elena Rivero 22/11/2021